P3 Health Partners Inc. Class A PIII

Moby summary of P3 Health Partners Inc.'s Q2 2026 earnings call

HENDERSON, Nev., August 10, 2026--P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the second quarter ended June 30, 2026.

HENDERSON, Nev., July 21, 2026--P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for second quarter 2026 on Monday, August 10, 2026. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day.

The latest update for P3 Health Partners lifts the internal fair value reference from $10.25 to $14.00, signaling a higher price target in current analyst models. That move is tied closely to recent commentary that balances optimism about 2026 execution, cleaner debt and equity structures, and higher EBITDA guidance with caution around how durable the reset in sentiment and valuation may be. As you read on, you will see how this evolving narrative might shape the way you track P3 Health...

President Trump’s 12-word remark, “I don’t think about Americans’ financial situation, I don’t think about anybody,” hit the wires, and the reaction showed up in the forgotten corners of the market, where micro-cap turnarounds priced like option contracts ripped higher on May 15 as traders rotated into beaten-down names with operational catalysts already in motion. ... Trump Rattled Markets Again and These 3 Forgotten Stocks Under $30 Were the Unlikely Winners

P3 Health Partners' (PIII) shares soared 182% amid heavy trading after the company posted overnight

Moby summary of P3 Health Partners Inc.'s Q1 2026 earnings call

P3 Health Partners Inc (PIII) reports robust Q1 performance, raises full-year outlook, and enhances balance sheet through strategic debt conversion.

The recent move to a reduced US$12.50 price target for P3 Health Partners, alongside an unchanged fair value estimate of US$10.25, signals a recalibration of expectations rather than a rewrite of the core story. Bullish analysts see the updated target as a reset on timing after weaker Q3 aEBITDA, while still pointing to underlying operational progress that they believe is not fully showing up in the numbers yet. As you read on, keep an eye on how these differing views shape the evolving...

P3 Health Partners has seen its price target revised to $12.50 even as fair value per share holds steady at $10.25 and the discount rate remains fixed at 12.5%. This underscores a more nuanced narrative around risk and long term potential. While analysts wrestle with a Q3 aEBITDA miss and stronger revenue growth expectations of roughly 11.1% vs prior 6.1%, the updated target reflects a recalibration of timing rather than a complete rethink of the growth story. Read on to see how you can stay...